Study #2020-0217
A Phase II Trial of Cetuximab for Patients with EGFR-Expressing Advanced or Metastatic Chordoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cetuximab
Description
This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chordoma, Metastatic Chordoma, Unresectable Chordoma
Study phase:
Phase II
Physician name:
Anthony Conley
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-866-403-3911
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.